Anyone searching for the effect of cannabidiol finds many promises and little context. This guide separates the two: it describes how cannabidiol is linked to the body's own signalling systems, what reviews say about the state of research, which side effects and interactions are described, and where the data ends. It makes no healing, effect or usage promises and gives no dosage figures.
What cannabidiol actually is, where it comes from and how it can be classified chemically is explained in the basics article What is CBD. Anyone interested in products can find our CBD flowers made from EU hemp with a laboratory certificate for every batch; they are not offered for health purposes.
CBD effects and the endocannabinoid system: what studies describe
The endocannabinoid system is a signalling system of the body itself. According to a review by Lu and Mackie (2016), it consists of cannabinoid receptors, mainly CB1 and CB2, of endogenous messenger substances such as anandamide and 2-AG, and of the enzymes that form and break down these messengers. It is involved in fine-tuning numerous processes in the nervous system.
Cannabidiol does not fit the simple picture of a "substance docking onto a receptor". The WHO Expert Committee noted in 2018 that cannabidiol apparently does not act directly on the CB1 receptor, where THC takes effect. A review by Britch, Babalonis and Walsh (2021) instead describes a large number of possible target structures, including further receptors, ion channels and enzymes. This very multitude is one reason why cannabidiol is studied so broadly, and at the same time a reason why no statement about an effect in humans can be derived from a mechanism observed in the lab.
State of research: many approaches, little robust data in humans
The review mentioned sums up the situation soberly: many claims about cannabidiol are not based on controlled clinical trials, but on the fact that the substance has numerous biological targets. In the authors' assessment, studies on most questions are few, often small and lack the controls needed for robust conclusions. On top of that, studies use different CBD sources and carrier substances, which makes comparison harder. What this looks like for a single question is shown by the state of research on CBD and quitting smoking.
A large part of the human data also comes from medical studies with an approved medicinal product. The EFSA points out that these results cannot be transferred to over-the-counter products, because different standards apply there. Accordingly, there is no proven effect for products from retail, whether flower, hash or oil, and CBDÍA does not describe one either.
Reading user reports and experiences correctly
Many people describe their personal impressions. Such reports are subjective and shaped by expectation, situation and product; some notice nothing, others describe unwanted effects. Experience reports can raise questions for research, but they do not replace proof and cannot be transferred to other people.
Does CBD get you high? Distinguishing it from intoxication
Cannabidiol is considered non-intoxicating. The WHO Expert Committee stated in 2018 that cannabidiol shows no evidence of abuse or dependence potential in humans. Cannabis's intoxicating effect is due to THC; what THC is and how it differs legally and chemically from cannabidiol is covered in a separate article.
Hemp products may contain traces of THC, with the content below the legal limit of 0.3 percent. How much THC a specific batch contains is shown by the laboratory certificate. The closely related cannabigerol is also considered non-intoxicating; details are in the article What is CBG.
Route of intake and bioavailability: what measurements show
How much cannabidiol reaches the blood depends strongly on the route of intake. A systematic review by Millar and colleagues (2018) on pharmacokinetics in humans describes that peak blood levels are reached faster after inhalation than after oral intake, and that fat-containing preparations influence absorption. At the same time, the authors emphasise how thin the data situation is: only a few studies provide pharmacokinetic values in humans at all, and their results differ from one another in places.
These measurements describe blood levels, not perceptible effects. They are therefore no basis for statements about the onset or duration of effect of a product. For context: CBD extracts are not approved as food in the EU, and oral use is not recommended here. How oils differ by spectrum and laboratory values is explained in the guide on CBD oil effects.
Side effects and interactions according to the EFSA and reviews
A review by Iffland and Grotenhermen (2017) confirms the favourable safety profile from clinical studies that is frequently described, but also names the most commonly reported side effects there: fatigue, diarrhoea and changes in appetite and weight. The authors point to a lack of long-term studies with larger numbers of participants. What authorities and studies note in detail about CBD side effects is summarised in a separate article.
Interactions are the most important safety point. Cannabidiol affects liver enzymes through which many medicines are also broken down; an analysis by Brown and Winterstein (2019) therefore rates the potential for interactions with common medications as high. In 2022, the EFSA also named open questions about the liver, gastrointestinal tract, hormonal and nervous system that need to be clarified before a safety assessment as a food. Anyone taking medication, who is pregnant, breastfeeding or has pre-existing conditions should clarify questions about cannabidiol with a doctor.
Legal status of cannabidiol in Germany
Cannabidiol is not listed in any schedule of the German Narcotics Act (BtMG) and is excluded from the definition of cannabis under Section 1 No. 8 (b) of the German Consumer Cannabis Act (KCanG). Hemp under Section 1 No. 9 KCanG requires varieties from the EU variety catalogue or at most 0.3 percent THC, and distribution that rules out abuse for intoxicating purposes. What this means for flowers is explained in the article CBD legal in Germany. CBDÍA only supplies products to adults aged 18 and over.
Transparency instead of promises: what a laboratory certificate shows
Because no product effect can be derived from research, CBDÍA relies on verifiable information: a laboratory certificate for every batch stating the content of CBD, CBDA, THC and other cannabinoids, the origin with country and cultivation type, and varieties from the EU variety catalogue for hemp. All laboratory certificates per batch are publicly available. A certificate proves measured values, not an effect.
In brief
Cannabidiol is linked to the endocannabinoid system and numerous other target structures, but robust data in humans is scarce and comes predominantly from medical studies. Side effects and a relevant potential for interactions with medications are described. According to the WHO's assessment, cannabidiol does not cause intoxication. There is no proven effect for products from retail.
This article is for general information purposes only and does not replace medical advice. Not legal advice. As of: September 2026.
